Defects in the c-ret proto-oncogene, a member of the protein tyrosine kinase receptor family, have recently been linked to two types of genetic syndromes, Hirschsprung's disease and the multiple endocrine neoplasia family of inherited cancers. RET/ptc2 is the product of a papillary thyroid carcinoma translocation event between the genes coding for c-ret and the type I regulatory subunit of protein kinase A (RI) (Lanzi, C., Borrello, M., Bongarzone, I., Migliazza, A., Fusco, A., Grieco, M., Santoro, M., Gambetta, R., Zunino, F., Della Porta, G., and Pierotti, M.(1992) Oncogene 7, 2189-2194). The resulting 596-residue protein contains the first two-thirds of RI and the entire tyrosine kinase domain of c-ret (RET). An in vivo assay of growth stimulatory effects was developed, which consisted of microinjecting a RET/ptc2 expression plasmid into the nuclei of 10T1/2 mouse fibroblasts and observing the incorporation of 5-bromodeoxyuridine. This assay was used to determine that only the dimerization domain of RI fused to RET is required for RET/ptc2's mitogenic activity. In addition, all of the reported Hirschsprung's disease point mutations in the RET (S289P, R421Q, and R496G) inactivate RET/ptc2 in our assay, confirming that these are loss of function mutations. Two tyrosines outside the conserved kinase core were also identified that are essential for full mitogenic activity of RET/ptc2. These two tyrosines, Tyr-350 and Tyr-586, are potential sites for Src homology 2 and phosphotyrosine binding domain interactions.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				M. Croyle, N. Akeno, J. A. Knauf, D. Fabbro, X. Chen, J. E. Baumgartner, H. A. Lane, and J. A. Fagin RET/PTC-Induced Cell Growth Is Mediated in Part by Epidermal Growth Factor Receptor (EGFR) Activation: Evidence for Molecular and Functional Interactions between RET and EGFR Cancer Res., June 1, 2008; 68(11): 4183 - 4191. [Abstract] [Full Text] [PDF]

				N. Mitsutake, M. Miyagishi, S. Mitsutake, N. Akeno, C. Mesa Jr, J. A. Knauf, L. Zhang, K. Taira, and J. A. Fagin BRAF Mediates RET/PTC-Induced Mitogen-Activated Protein Kinase Activation in Thyroid Cells: Functional Support for Requirement of the RET/PTC-RAS-BRAF Pathway in Papillary Thyroid Carcinogenesis Endocrinology, February 1, 2006; 147(2): 1014 - 1019. [Abstract] [Full Text] [PDF]

				E Puxeddu, J A Knauf, M A Sartor, N Mitsutake, E P Smith, M Medvedovic, C R Tomlinson, S Moretti, and J A Fagin RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response Endocr. Relat. Cancer, June 1, 2005; 12(2): 319 - 334. [Abstract] [Full Text] [PDF]

				Z. Liu, J. Falola, X. Zhu, Y. Gu, L. T. Kim, G. A. Sarosi, T. Anthony, and F. E. Nwariaku Antiproliferative Effects of Src Inhibition on Medullary Thyroid Cancer J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3503 - 3509. [Abstract] [Full Text] [PDF]

				M. Encinas, R. J. Crowder, J. Milbrandt, and E. M. Johnson Jr. Tyrosine 981, a Novel Ret Autophosphorylation Site, Binds c-Src to Mediate Neuronal Survival J. Biol. Chem., April 30, 2004; 279(18): 18262 - 18269. [Abstract] [Full Text] [PDF]

				J. P. Russell, J. B. Engiles, and J. L. Rothstein Proinflammatory Mediators and Genetic Background in Oncogene Mediated Tumor Progression J. Immunol., April 1, 2004; 172(7): 4059 - 4067. [Abstract] [Full Text] [PDF]

				E. Puxeddu, N. Mitsutake, J. A. Knauf, S. Moretti, H. W. Kim, K. A. Seta, D. Brockman, L. Myatt, D. E. Millhorn, and J. A. Fagin Microsomal Prostaglandin E2 Synthase-1 Is Induced by Conditional Expression of RET/PTC in Thyroid PCCL3 Cells through the Activation of the MEK-ERK Pathway J. Biol. Chem., December 26, 2003; 278(52): 52131 - 52138. [Abstract] [Full Text] [PDF]

				J. R Hansford and L. M Mulligan Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis J. Med. Genet., November 1, 2000; 37(11): 817 - 827. [Abstract] [Full Text]

				S Srinivas, Z Wu, C. Chen, V D'Agati, and F Costantini Dominant effects of RET receptor misexpression and ligand-independent RET signaling on ureteric bud development Development, January 4, 1999; 126(7): 1375 - 1386. [Abstract] [PDF]

				A. H. Fischer, J. A. Bond, P. Taysavang, O. E. Battles, and D. Wynford-Thomas Papillary Thyroid Carcinoma Oncogene (RET/PTC) Alters the Nuclear Envelope and Chromatin Structure Am. J. Pathol., November 1, 1998; 153(5): 1443 - 1450. [Abstract] [Full Text] [PDF]

				D. H. J. van Weering, T. C. Moen, I. Braakman, P. D. Baas, and J. L. Bos Expression of the Receptor Tyrosine Kinase Ret on the Plasma Membrane Is Dependent on Calcium J. Biol. Chem., May 15, 1998; 273(20): 12077 - 12081. [Abstract] [Full Text] [PDF]

				K. Durick, G. N. Gill, and S. S. Taylor Shc and Enigma Are Both Required for Mitogenic Signaling by Ret/ptc2 Mol. Cell. Biol., April 1, 1998; 18(4): 2298 - 2308. [Abstract] [Full Text]

				Q. Tong, S. Xing, and S. M. Jhiang Leucine Zipper-mediated Dimerization Is Essential for the PTC1 Oncogenic Activity J. Biol. Chem., April 4, 1997; 272(14): 9043 - 9047. [Abstract] [Full Text] [PDF]

				N. Asai, H. Murakami, T. Iwashita, and M. Takahashi A Mutation at Tyrosine 1062in MEN2A-Ret and MEN2B-Ret Impairs Their Transforming Activity and Association with Shc Adaptor Proteins J. Biol. Chem., July 26, 1996; 271(30): 17644 - 17649. [Abstract] [Full Text] [PDF]

				R.-y. Wu, K. Durick, Z. Songyang, L. C. Cantley, S. S. Taylor, and G. N. Gill Specificity of LIM Domain Interactions with Receptor Tyrosine Kinases J. Biol. Chem., July 5, 1996; 271(27): 15934 - 15941. [Abstract] [Full Text] [PDF]

				K. Durick, R.-Y. Wu, G. N. Gill, and S. S. Taylor Mitogenic Signaling by Ret/ptc2 Requires Association with Enigma via a LIM Domain J. Biol. Chem., May 31, 1996; 271(22): 12691 - 12694. [Abstract] [Full Text] [PDF]

				X. Liu, Q. C. Vega, R. A. Decker, A. Pandey, C. A. Worby, and J. E. Dixon Oncogenic RET Receptors Display Different Autophosphorylation Sites and Substrate Binding Specificities J. Biol. Chem., March 8, 1996; 271(10): 5309 - 5312. [Abstract] [Full Text] [PDF]